To compare the time to next treatment between patients with previously untreated, low tumor burden FL who receive the study drug epcoritamab versus those who do not receive epcoritamab and are monitored only.
Histologically diagnosed follicular lymphoma grade 1-3a
Within 6 months from the diagnosis of follicular lymphoma
Have no prior systemic treatment for lymphoma
Stage II (non-contiguous), III or IV disease
Known active central nervous system lymphoma or leptomeningeal disease
Adequately treated localized skin cancer without evidence of disease.
Adequately treated breast cancer without evidence of disease.
Adequately treated prostate cancer or monitored with watch and wait for low risk disease without evidence of progressive disease.
Single group
Epcoritamab
DrugGiven by Injection
Observation
Other interventionParticipant will be closely monitored until the disease gets worse and requires treatment, as determined by your treating doctor or at your request.
Safety and adverse events (AEs).
Incidence of Adverse Events, Graded According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) Version (v) 5.0
Click on the lead sponsor to view all of their trials.
M.D. Anderson Cancer Center
Lead sponsor
Genmab
Collaborator
This trial is not recruiting at the moment. You can still explore other options:
